The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
A Stengel, W Kern, T Haferlach, M Meggendorfer… - Leukemia, 2017 - nature.com
A Stengel, W Kern, T Haferlach, M Meggendorfer, A Fasan, C Haferlach
Leukemia, 2017•nature.comAlterations in TP53 have been described in many cancer types including hematological
neoplasms. We aimed at comparing TP53 mutations (mut) and deletions (del) in a large
cohort of patients with hematological malignancies (n= 3307), including AML (n= 858), MDS
(n= 943), ALL (n= 358), CLL (n= 1148). Overall, alterations in TP53 were detected in
332/3307 cases (10%). The highest frequency was observed in ALL (total: 19%; mut+ del:
6%; mut only: 8%; del only: 5%) and AML (total: 13%; mut+ del: 5%; mut only: 7%; del only …
neoplasms. We aimed at comparing TP53 mutations (mut) and deletions (del) in a large
cohort of patients with hematological malignancies (n= 3307), including AML (n= 858), MDS
(n= 943), ALL (n= 358), CLL (n= 1148). Overall, alterations in TP53 were detected in
332/3307 cases (10%). The highest frequency was observed in ALL (total: 19%; mut+ del:
6%; mut only: 8%; del only: 5%) and AML (total: 13%; mut+ del: 5%; mut only: 7%; del only …
Abstract
Alterations in TP53 have been described in many cancer types including hematological neoplasms. We aimed at comparing TP53 mutations (mut) and deletions (del) in a large cohort of patients with hematological malignancies (n= 3307), including AML (n= 858), MDS (n= 943), ALL (n= 358), CLL (n= 1148). Overall, alterations in TP53 were detected in 332/3307 cases (10%). The highest frequency was observed in ALL (total: 19%; mut+ del: 6%; mut only: 8%; del only: 5%) and AML (total: 13%; mut+ del: 5%; mut only: 7%; del only: 1%), whereas TP53 alterations occurred less frequently in CLL (total: 8%) and MDS (total: 7%). TP53 mutations were significantly more frequent in patients⩾ 60 vs< 60 years in AML (9% vs 2%, P< 0.001) and ALL (12% vs 6%, P< 0.001). TP53mut+ del had a significant negative impact on overall survival in all entities, whereas differences were observed regarding TP53mut only or TP53del only: TP53mut only impacted survival in AML (36 vs 9 months, P< 0.001) and MDS (65 vs 19 months, P< 0.001), TP53del only in CLL (not reached vs 64 months, P= 0.008) and MDS (65 vs 24 months, P= 0.011). As substantial differences between the entities are observed regarding correlation to age and survival, we suggest evaluation of both TP53 deletion and mutation status.
nature.com